Ind-Swift Laboratories Ltd
INDSWFTLAB NSE
Ind-Swift Laboratories Ltd
HealthcareNSE: INDSWFTLAB BSE: 532305 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹1,973 Cr
Volatility
Moderate
P/E Ratio
42.77
EBITDA
₹34.09 Cr
Return on Equity
21.36%
Debt to Equity
0.01
Book Value
₹159.17
52W High
₹248.45
52W Low
₹87.15
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Ind-Swift Laboratories Ltd insights
45 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
Weaknesses
6- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -6.37% over past five years.
- Company has a low return on equity of 6.11% over last 3 years.
- Earnings include an other income of Rs.36.0 Cr.
- Debtor days have increased from 89.4 to 113 days.
- Working capital days have increased from 94.1 days to 165 days
Growth Rate
Revenue Growth
-0.28% ↗
Net Income Growth
-85.66% ↘
Cash Flow Change
84.39% ↗
ROE
-52.80% ↘
ROCE
-68.07% ↘
EBITDA Margin (Avg.)
-48.65% ↘
Quarterly Results
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 304 | 310 | 290 | 288 | 529 | 33 | 12 | 129 | 138 | 153 | 153 | 151 | 170 |
| Expenses | 241 | 250 | 224 | 236 | 437 | 43 | 24 | 135 | 147 | 149 | 151 | 147 | 149 |
| Operating Profit | 64 | 60 | 66 | 52 | 91 | -10 | -12 | -7 | -9 | 4 | 1 | 4 | 21 |
| OPM % | 21% | 19% | 23% | 18% | 17% | -29% | -99% | -5% | -7% | 2.4% | 1% | 2.8% | 12% |
| Other Income | -16 | 6 | 7 | 7 | 458 | 11 | 13 | 16 | 220 | 15 | 18 | 22 | -3 |
| Interest | 22 | 20 | 21 | 21 | 3 | 0 | 0 | 10 | -27 | 1 | 2 | 1 | -2 |
| Depreciation | 9 | 14 | 13 | 14 | 20 | 0 | 0 | 6 | 7 | 7 | 7 | 9 | 8 |
| PBT | 16 | 32 | 39 | 24 | 527 | 1 | 1 | -7 | 230 | 10 | 10 | 16 | 12 |
| Tax % | 255% | 45% | 18% | 19% | 6% | -3% | 31% | -16% | 4% | 17% | 22% | 42% | -26% |
| Net Profit | -25 | 17 | 32 | 19 | 494 | 1 | 0 | -5 | 222 | 9 | 8 | 10 | 15 |
| EPS in Rs | -4.25 | 2.92 | 5.36 | 3.29 | 83.55 | 0.16 | 0.07 | -0.93 | 36.67 | 1.45 | 0.98 | 1.17 | 1.74 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 660 | 653 | 716 | 765 | 757 | 780 | 891 | 1,039 | 1,207 | 1,281 | 562 | 641 |
| Expenses | 571 | 546 | 610 | 631 | 630 | 635 | 709 | 837 | 978 | 1,029 | 581 | 596 |
| Operating Profit | 89 | 107 | 106 | 134 | 126 | 144 | 183 | 202 | 229 | 252 | -19 | 45 |
| OPM % | 13% | 16% | 15% | 18% | 17% | 19% | 21% | 19% | 19% | 20% | -3.5% | 7% |
| Other Income | -31 | 1 | 15 | 16 | 120 | 33 | 23 | 37 | 7 | 434 | 305 | 36 |
| Interest | 117 | 106 | 88 | 28 | 92 | 107 | 100 | 96 | 92 | 51 | 3 | 1 |
| Depreciation | 84 | 85 | 88 | 87 | 104 | 90 | 87 | 131 | 57 | 53 | 24 | 31 |
| PBT | -143 | -83 | -55 | 36 | 50 | -20 | 18 | 13 | 87 | 582 | 258 | 49 |
| Tax % | -17% | -29% | -29% | 39% | 42% | 7% | 117% | 117% | 45% | 28% | 3% | 16% |
| Net Profit | -119 | -59 | -39 | 22 | 29 | -21 | -3 | -2 | 48 | 421 | 250 | 41 |
| EPS in Rs | -29.14 | -14.33 | -8.75 | 4.85 | 6.09 | -3.59 | -0.53 | -0.36 | 8.06 | 71.24 | 41.32 | 4.77 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 42 | 42 | 45 | 46 | 48 | 60 | 60 | 60 | 60 | 59 | 69 | 87 |
| Reserves | 553 | 476 | 486 | 507 | 540 | 581 | 544 | 541 | 622 | 872 | 1,104 | 1,297 |
| Borrowings | 1,413 | 1,457 | 1,242 | 1,083 | 1,148 | 1,031 | 1,005 | 953 | 862 | 17 | 41 | 18 |
| Other Liabilities | 236 | 240 | 364 | 387 | 188 | 198 | 210 | 247 | 280 | 217 | 224 | 271 |
| Total Liabilities | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,165 | 1,438 | 1,673 |
| Fixed Assets | 1,117 | 1,099 | 1,042 | 934 | 914 | 843 | 753 | 630 | 587 | 8 | 273 | 306 |
| CWIP | 113 | 78 | 70 | 69 | 20 | 11 | 19 | 10 | 8 | 0 | 0 | 10 |
| Investments | 18 | 18 | 18 | 18 | 19 | 17 | 36 | 29 | 30 | 111 | 213 | 248 |
| Other Assets | 997 | 1,020 | 1,007 | 1,002 | 972 | 998 | 1,011 | 1,131 | 1,199 | 1,047 | 952 | 1,110 |
| Total Assets | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,165 | 1,438 | 1,673 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 98 | 79 | 96 | 73 | -64 | 125 | 135 | 150 | 195 | -163 | -25 | -70 |
| Investing | -35 | -29 | -31 | -17 | -12 | -9 | -10 | 5 | -13 | -104 | -110 | -73 |
| Financing | -64 | -48 | -69 | -62 | 100 | -133 | -124 | -141 | -186 | 699 | 69 | 142 |
| Net Cash Flow | -1 | 3 | -4 | -6 | 23 | -17 | 1 | 14 | -4 | 431 | -66 | -1 |
| Free Cash Flow | 59 | 49 | 63 | 52 | -79 | 114 | 131 | 137 | 182 | -205 | -51 | -156 |
| CFO/OP | 111 | 74 | 90 | 54 | -51 | 87 | 73 | 74 | 85 | -65 | 131 | -140 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 215 | 208 | 182 | 194 | 169 | 186 | 177 | 160 | 153 | 48 | 107 | 113 |
| Inventory Days | 312 | 368 | 305 | 291 | 284 | 313 | 301 | 288 | 242 | 6 | 145 | 191 |
| Days Payable | 120 | 137 | 91 | 118 | 114 | 123 | 111 | 118 | 113 | 52 | 140 | 188 |
| Cash Conversion Cycle | 407 | 439 | 396 | 367 | 339 | 375 | 367 | 330 | 282 | 2 | 112 | 116 |
| Working Capital Days | 141 | -26 | -97 | -49 | 217 | 248 | 253 | 253 | 234 | 2 | 115 | 165 |
| ROCE % | 1% | 2% | 2% | 4% | 4% | 5% | 7% | 7% | 13% | 20% | 1% | 5% |
Documents
2
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
5 May - Postal ballot passed four special resolutions appointing MDs and approving remuneration on 5 May 2026. 5 May - Postal ballot passed four special resolutions appointing MDs and approving remuneration on 5 May 2026.
3
Disclosures Under Regulation 29(2) Of The SEBI (Substantial Acquisition Of Shares And Takeover) Regulations, 2011
22 Apr - HCP Investments disclosed sale of 6,503,423 Ind-Swift shares, 7.5% stake, on 21 April 2026. 22 Apr - HCP Investments disclosed sale of 6,503,423 Ind-Swift shares, 7.5% stake, on 21 April 2026.
4
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
21 Apr - HCP Investments disclosed disposal of 6,503,423 Ind-Swift shares, representing 7.5%, on 21 April 2026. 21 Apr - HCP Investments disclosed disposal of 6,503,423 Ind-Swift shares, representing 7.5%, on 21 April 2026.
5
Disclosures Under Regulation 29(2) Of The SEBI (Substantial Acquisition Of Shares And Takeover) Regulations, 2011
11h - HCP Investments disclosed sale of 6,503,423 Ind-Swift shares, 7.5% stake, on 21 April 2026. 11h - HCP Investments disclosed sale of 6,503,423 Ind-Swift shares, 7.5% stake, on 21 April 2026.
5
Corrigendum To The Notice Of 01/2026-27 Extra-Ordinary General Meeting (EGM Notice) Dated July 10 2026 29 Jul 2026
General_Announcements
Frequently Asked Questions about Ind-Swift Laboratories Ltd
What does Ind-Swift Laboratories Ltd do?
Incorporated in 1995, Ind-Swift Laboratories Ltd is in the business of Bulk Drugs & Pharmaceuticals[1]
Where is Ind-Swift Laboratories Ltd (INDSWFTLAB) listed?
Ind-Swift Laboratories Ltd is listed on the Indian stock exchanges. It is listed on NSE: INDSWFTLAB and BSE: 532305. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Ind-Swift Laboratories Ltd belong to?
Ind-Swift Laboratories Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd has a market capitalisation of approximately ₹1972.93 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Ind-Swift Laboratories Ltd?
The Price-to-Earnings (PE) ratio of Ind-Swift Laboratories Ltd is 42.77. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Ind-Swift Laboratories Ltd?
Over the past 52 weeks, Ind-Swift Laboratories Ltd has traded between a low of ₹87.15 and a high of ₹248.45. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd has a Return on Equity (ROE) of 21.36%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Ind-Swift Laboratories Ltd on Tapetide?
On Tapetide, you can view Ind-Swift Laboratories Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1995, Ind-Swift Laboratories Ltd is in the business of Bulk Drugs & Pharmaceuticals[1]
Website indswiftlabs.com
CEO Mr. Navrattan R. Munjal
Employees 1,246
Listed 1997-07-02
Face Value ₹ 10
Issued Size 8,16,11,558